XGES:LSE:LSE-Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc GBP (GBP)

ETF | Others |

Last Closing

USD 24.5625

Change

+0.24 (+0.99)%

Market Cap

N/A

Volume

2.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.14 (+0.12%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.12 (+0.64%)

USD 557.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.01 (+0.09%)

USD 496.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.45 (-0.63%)

USD 266.08B
0QZO:LSE 0QZO

+1.60 (+1.80%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.21 (+0.69%)

USD 209.75B
0QZ3:LSE Qualcomm Inc.

+1.37 (+0.83%)

USD 202.26B
0R24:LSE Intel Corp.

+0.42 (+2.15%)

USD 196.14B

ETFs Containing XGES:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.43% 46% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.43% 44% F 49% F
Trailing 12 Months  
Capital Gain 3.00% 26% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.00% 24% F 37% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.10% 15% F 27% F
Dividend Return -3.10% 14% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.77% 56% F 73% C
Risk Adjusted Return -26.36% 16% F 24% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.